Pasithea Therapeutics Corp Dossier - Source-backed chat

Pasithea Therapeutics Corp

KTTANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.51

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.49Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $16.3M

Enterprise Value −$29.3M

Shares Outstanding 31.3M diluted

Next Earnings Date15 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Pasithea Therapeutics is a clinical-stage biotechnology company focused on developing PAS-004, a next-generation macrocyclic MEK inhibitor, for neurofibromatosis type 1 (NF1) and advanced solid tumors. Following a transformative $60 million public offering in late 2025, the company has built a robust cash runway of $50.4 million (as of Q1 2026) that is expected to fund operations into at least the first half of 2028. This financial stability, combined with recent FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations, significantly de-risks the clinical development of PAS-004. With key clinical readouts expected in late 2026, the stock offers an asymmetric risk-reward profile at its current micro-cap valuation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.00

Mean target$3.00

High · most bullish analyst$3.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

PAS-004 clinical trials reveal unexpected safety concerns or dose-limiting toxicities, or fail to show meaningful efficacy in NF1-PN patients. The company is forced to halt development or faces severe delays. Additionally, the company fails to regain compliance with Nasdaq's minimum bid price requirement and is delisted to the OTC market, severely reducing liquidity. R&D expenses continue to escalate, accelerating the cash burn and shortening the runway.

Base CaseCentral scenario

$2.5050%

PAS-004 shows a competitive safety profile and comparable efficacy (stable disease and partial responses) in the ongoing Phase 1/1b trial. The company successfully completes Part A dose escalation, selects the RP2D, and initiates Part B. To maintain its Nasdaq listing, the company implements a reverse stock split or regains compliance organically as clinical milestones approach. The cash runway remains sufficient to fund operations through 2027, allowing the company to reach key clinical inflection points without immediate dilutive financing.

Bull CaseUpside scenario

$3.0030%

PAS-004 demonstrates superior safety, tolerability, and efficacy compared to approved MEK inhibitors (such as Koselugo) in the Phase 1/1b NF1 trial. The macrocyclic design successfully avoids the severe class-effect toxicities of conventional MEK inhibitors, allowing for long-term dosing. The company rapidly transitions to a registrational Part B phase, and the FDA grants accelerated approval. The cash runway is preserved, and the company secures a lucrative global co-development partnership with a major pharmaceutical firm.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong cash position of $50.4 million as of March 31, 2026, providing a runway into at least H1 2028.
Lead asset PAS-004 has received FDA Fast Track and Rare Pediatric Disease designations for NF1, and Orphan Drug designation for ALS.
Differentiated macrocyclic design of PAS-004 aims to offer a wider therapeutic window and better tolerability than existing MEK inhibitors.
Highly experienced clinical leadership, highlighted by the appointment of Dr. Kartik Krishnan (former CEO of OncoNano and CMO of Arcus Biosciences) as Chief Medical Officer in May 2026.

Key Investment Risks

High clinical development risk typical of early-stage oncology and rare disease therapeutics.
Nasdaq delisting risk due to the common stock trading below the $1.00 minimum bid price requirement.
Potential dilution from outstanding warrants, including pre-funded warrants from the late 2025 offering.
Intense competition in the MEK inhibitor space from established pharmaceutical companies.

Thesis Invalidation Triggers

Failure of PAS-004 to demonstrate acceptable safety or preliminary efficacy in the Phase 1/1b NF1 trial.
Inability to regain compliance with Nasdaq's minimum bid price requirement, resulting in delisting.
Departure of key executive leadership, particularly the CEO or newly appointed CMO.
A material acceleration in cash burn that reduces the projected runway to less than 18 months.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.